title: Cerebro-protective effects of ENA713, a novel acetylcholinesterase inhibitor, in closed head injury in the rat.
abstract: Focal ischemic brain damage and diffuse brain swelling occur in severe cases of traumatic head injury. Ischemia decreases brain acetylcholine (ACh) levels and head trauma upregulates acetylcholinesterase (AChE) in experimental animal models. The present study determined whether a brain-selective AChE inhibitor, ENA713, given once, up to 2 h after closed head injury (CHI) could reduce the vasogenic edema and accelerate recovery from neurological deficits induced by the injury in rats. ENA713 1-5 mg/kg produced a dose-related inhibition of AChE ranging from 40-85% in the cortex and hippocampus. Doses of 1, 2 and 5 mg/kg, significantly reduced the motor and neurological deficits and speeded recovery, as indicated by measurements made 7 and 14 days after injury. The two larger doses were still effective when injected 1 or 2 h after CHI. The acceleration by ENA713 of recovery of motor function was independent of its reduction in body temperature and was prevented by the simultaneous injection of mecamylamine (2.5 mg/kg), but not by scopolamine (0.2 or 1 mg/kg). Edema in the contused hemisphere (24 h after injury) and disruption of the blood brain barrier (4 h after injury) were significantly reduced (about 50%) by doses of 2 and 5 mg/kg, but not by 1 mg/kg. The data support the hypothesis that ENA713 exerts a neuroprotective effect in brain injury by preventing the decrease in cholinergic activity in cerebral vessels and in neurones.
authors.affiliation: Department of Pharmacology, School of Pharmacy, The Hebrew University of Jerusalem, Jerusalem 91120, Israel.
authors.forename: Y
authors.initials: Y
authors.lastname: Chen
authors.forename: E
authors.initials: E
authors.lastname: Shohami
authors.forename: R
authors.initials: R
authors.lastname: Bass
authors.forename: M
authors.initials: M
authors.lastname: Weinstock
mesh_terms: D000818:Animals; D001812:Blood-Brain Barrier / Q000187:drug effects; D001831:Body Temperature; D001929:Brain Edema / Q000473:pathology; D002219:Carbamates / Q000627:therapeutic use*; D002540:Cerebral Cortex / Q000187:drug effects / Q000201:enzymology; D002800:Cholinesterase Inhibitors / Q000627:therapeutic use*; D016489:Head Injuries, Closed / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D006624:Hippocampus / Q000187:drug effects / Q000201:enzymology; D008297:Male; D009068:Movement / Q000187:drug effects / Q000502:physiology; D048448:Phenylcarbamates; D051381:Rats; D012018:Reflex / Q000187:drug effects / Q000502:physiology; D000068836:Rivastigmine; D012601:Scopolamine / Q000494:pharmacology
chemical_list: D002219:Carbamates; D002800:Cholinesterase Inhibitors; D048448:Phenylcarbamates; D012601:Scopolamine; D000068836:Rivastigmine